Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients with type 2 diabetes mellitus (Hba1c 7 %- 9%). Patients receiving dipeptidyl peptidase-4 inhibitors, metformin ± basal insulin.~Patients with peripheral neuropathy and not on SGLT2 inhibitor treatment. Patients aged between 18 years old to 65 years old.~Exclusion Criteria:~* Breastfeeding female.~* Pregnant female.~* Estimated Glomerular Filtration Rate less than 45 mL/minute/1.73 m2.~* Patients with type 1 diabetes mellitus.~* Patients with diabetic ketoacidosis.~* Patients with urinary tract infections.~* Dehydrated patients till normalized.~* Lower limb amputation patients.~* SGLT2 inhibitors hypersensitivity.~* Severe hepatic patients.~* Patients on neuroprotective drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Control group (Type: NO_INTERVENTION): include twenty-five patients who will receive placebo tablets once daily for three months, plus their antidiabetic drugs ( Dpp4 inhibitor and metformin)
- Empagliflozin group (Type: EXPERIMENTAL): include twenty five patients who will receive Empagloflozin 25 mg once daily for three months, plus their antidiabetic drugs ( Dpp4 inhibitor and metformin)

Based on this trial design, predict the completion outcome and termination type (if applicable).